Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001558370-21-016323
Filing Date
2021-11-24
Accepted
2021-11-24 16:02:18
Documents
9

Document Format Files

Seq Description Document Type Size
1 DEFA14A tmb-20211124xdefa14a.htm DEFA14A 27297
2 GRAPHIC tmb-20211124xdefa14a002.jpg GRAPHIC 41891
3 GRAPHIC tmb-20211124xdefa14a001.jpg GRAPHIC 34613
4 GRAPHIC tmb-20211124xdefa14a003.jpg GRAPHIC 50203
5 GRAPHIC tmb-20211124xdefa14a006.jpg GRAPHIC 52889
6 GRAPHIC tmb-20211124xdefa14a008.jpg GRAPHIC 51052
7 GRAPHIC tmb-20211124xdefa14a005.jpg GRAPHIC 55586
8 GRAPHIC tmb-20211124xdefa14a004.jpg GRAPHIC 54812
9 GRAPHIC tmb-20211124xdefa14a007.jpg GRAPHIC 70564
  Complete submission text file 0001558370-21-016323.txt   596605
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

EIN.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: DEFA14A | Act: 34 | File No.: 001-35023 | Film No.: 211446365
SIC: 2834 Pharmaceutical Preparations